References
- Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet (London England) [Internet]. 2021 Apr 24 [cited 2021 Dec 12];397( 10284):1577–1590. Available from: https://pubmed.ncbi.nlm.nih.gov/33667416/
- Hampel H, Cummings J, Blennow K, et al. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol. Internet]. 2021 Sep 1 [cited. 2021 Dec 11] ;179:580–589. https://doi.org/10.1038/s41582-021-00520-w.
- Hampel H, Hardy J, Blennow K, et al. The Amyloid-β Pathway in Alzheimer’s Disease. Mol Psychiatry [Internet]. 2021 [cited 2021 Dec 11]; Available from: https://pubmed.ncbi.nlm.nih.gov/34456336/
- Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. Internet]. 2018 Apr 1 [cited. 2021 Dec 11];144:535–562. https://doi.org/10.1016/j.jalz.2018.02.018.
- Alafuzoff I, Kovacs GG. Comorbidities. Handb Clin Neurol. 2018;145:573–577.
- Rabinovici GD, Carrillo MC, Forman M, et al. Multiple comorbid neuropathologies in the setting of Alzheimer’s disease neuropathology and implications for drug development. Alzheimer’s Dement (New York N Y) [Internet]. 2016 Jan 1 [cited 2021 Jan 1];3( 1):83–91. Available from: https://pubmed.ncbi.nlm.nih.gov/29067320/
- Wong YC, Krainc D. α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. Internet]. 2017 Feb 7 [cited. 2021 Dec 11];232:1–13. https://doi.org/10.1038/nm.4269.
- Visanji NP, Lang AE, Kovacs GG. Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. Transl Neurodegener. Internet]. 2019 Sep 4 [cited. 2021 Dec 11];81: https://doi.org/10.1186/s40035-019-0172-x.
- Kovacs GG. Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine. Int J Mol Sci. Internet]. 2016 Feb 2 [cited. 2021 Dec 11];172:189. https://doi.org/10.3390/ijms17020189.
- Baldacci F, Mazzucchi S, Della Vecchia A, et al. The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases [Internet]. Vol. 20, Expert Review of Molecular Diagnostics. Taylor and Francis Ltd; 2020 [cited 2020 Apr 23]. p. 421–441. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32066283
- Vergallo A, Bun RS, Toschi N, et al. Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer’s disease biomarkers. Alzheimer’s Dement. 2018 Dec 1;14(12):1623–1631.
- Larson ME, Sherman MA, Greimel S, et al. Soluble α-synuclein is a novel modulator of Alzheimer’s disease pathophysiology. J Neurosci. Internet]. 2012 Jul 25 [cited. 2021 Dec 11];3230:10253–10266. https://doi.org/10.1523/JNEUROSCI.0581-12.2012.
- Twohig D, Nielsen HM. α-synuclein in the pathophysiology of Alzheimer’s disease. Vol. 14. London, WC1 United Kingdom: Molecular Neurodegeneration. BioMed Central Ltd.; 2019.
- Toledo JB, Korff A, Shaw LM, et al. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease. Acta Neuropathol. Internet]. 2013 Nov [cited. 2021 Dec];1265:683–697. https://doi.org/10.1007/s00401-013-1148-z.
- Rodriguez-Vieitez E, Nielsen HMABAPOEV. Tau and α-Synuclein. Adv Exp Med Biol. 2019 [[cited 2021 Dec 11]];1184:177–186. Internet https://pubmed.ncbi.nlm.nih.gov/32096038/
- Lashuel HA, Overk CR, Oueslati A, et al. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. Internet]. 2013 Jan [cited. 2021 Dec];141:38–48. https://doi.org/10.1038/nrn3406.
- Stephens AD, Zacharopoulou M, Moons R, et al. Extent of N-terminus exposure of monomeric alpha-synuclein determines its aggregation propensity. Nat Commun. Internet]. 2020 Dec 1 [cited. 2021 Dec 11];111: https://doi.org/10.1038/s41467-020-16564-3.
- Bendor JT, Logan TP, Edwards RH. The function of α-synuclein. Neuron. 2013 Sep 18 [[cited 2021 Dec 11]];79(6):1044–1066. Internet https://pubmed.ncbi.nlm.nih.gov/24050397/
- Stefanis L. α-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med. Internet]. 2012 [cited. 2021];22:a009399–a009399. DOI: https://doi.org/10.1101/cshperspect.a009399.
- Fusco G, Pape T, Stephens AD, et al. Structural basis of synaptic vesicle assembly promoted by α-synuclein. Nat Commun. Internet]. 2016 Sep 19 [cited. 2021 Dec 11];71: https://doi.org/10.1038/ncomms12563.
- Lautenschläger J, Kaminski CF, Kaminski Schierle GS. α-synuclein - regulator of exocytosis, endocytosis, or both? Trends Cell Biol. Internet]. 2017 Jul 1 [cited. 2021 Dec 11];277:468–479. https://doi.org/10.1016/j.tcb.2017.02.002.
- Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. Internet]. 2013 [cited. 2021];5017465:45–51. DOI: https://doi.org/10.1038/nature12481.
- Aguzzi A, Montrasio F, Kaeser PS. Prions: health scare and biological challenge. Nat Rev Mol Cell Biol. Internet]. 2001 Feb [cited. 2021 Dec];22:118–126. https://doi.org/10.1038/35052063.
- Giacomelli C, Daniele S, Martini C. Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases. Biochem Pharmacol. Internet]. 2017 May 1 [cited. 2021 Dec 11];131:1–15. https://doi.org/10.1016/j.bcp.2017.01.017.
- Benussi L, Ghidoni R, Paterlini A, et al. Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation. Exp Cell Res. Internet]. 2005 Aug 1 [cited. 2021 Dec 11];3081:78–84. https://doi.org/10.1016/j.yexcr.2005.04.021.
- Tsigelny IF, Crews L, Desplats P, et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer’s and Parkinson’s diseases. PLoS One. Internet]. 2008 Sep 4 [cited. 2021 Dec 11];39:e3135. https://doi.org/10.1371/journal.pone.0003135.
- Mandal PK, Pettegrew JW, Masliah E, et al. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer’s and Parkinson’s in dementia with Lewy body disease. Neurochem Res. Internet]. 2006 [cited. 2021];319:1153–1162. DOI: https://doi.org/10.1007/s11064-006-9140-9.
- Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. Internet]. 2003 Apr 25 [cited. 2021 Dec 11];35619:636–640. https://doi.org/10.1126/science.1082324.
- Jensen PH, Hager H, Nielsen MS, et al. alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem. Internet]. 1999 Sep 3 [cited. 2021 Dec 11];27436:25481–25489. https://doi.org/10.1074/jbc.274.36.25481.
- Piccarducci R, Pietrobono D, Pellegrini C, et al. High levels of β -amyloid, tau, and phospho-tau in red blood cells as biomarkers of neuropathology in senescence-accelerated mouse. Oxid Med Cell Longev.Internet]. 2019 [cited. 2021];2019:1–16. DOI:https://doi.org/10.1155/2019/5030475.
- Daniele S, Frosini D, Pietrobono D, et al. α-synuclein heterocomplexes with β-amyloid are increased in red blood cells of parkinson’s disease patients and correlate with disease severity. Front Mol Neurosci. Internet]. 2018 Feb 22 [cited. 2021 Dec 11];11: https://doi.org/10.3389/fnmol.2018.00053.
- Baldacci F, Daniele S, Piccarducci R, et al. Potential diagnostic value of red blood cells α-synuclein heteroaggregates in alzheimer’s disease. Mol Neurobiol. Internet]. 2019 Sep 15 [cited. 2020 Jul 26];569:6451–6459. https://doi.org/10.1007/s12035-019-1531-4.
- Daniele S, Baldacci F, Piccarducci R, et al. α-synuclein heteromers in red blood cells of alzheimer’s disease and lewy body dementia patients. J Alzheimers Dis. 2021 [cited 2021 Dec 11];80(2):885–893. Internet https://doi.org/10.3233/JAD-201038.
- Halliday GM, Holton JL, Revesz T, et al. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. Internet]. 2011 Aug [cited. 2021 Dec];1222:187–204. https://doi.org/10.1007/s00401-011-0852-9.
- Jellinger KA. Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders. J Neural Transm. Internet]. 2019 Aug 1 [cited. 2021 Dec 11];1268:933–995.
- Spillantini MG, Schmidt ML, Lee VMY, et al. Alpha-synuclein in Lewy bodies. Nature. Internet]. 1997 [cited. 2021];3886645:839–840. DOI: https://doi.org/10.1038/42166.
- Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. Internet]. 2003 Mar [cited. 2021 Dec];242:197–211. https://doi.org/10.1016/S0197-4580(02)00065-9.
- Jellinger KA. Multiple system atrophy: an oligodendroglioneural synucleinopathy1. J Alzheimers Dis. 2018 [[cited 2021 Dec 11]];62(3):1141–1179. Internet https://pubmed.ncbi.nlm.nih.gov/28984582/
- Trojanowski JQ, Revesz T. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol. Internet]. 2007 [cited. 2021];336:615–620. DOI: https://doi.org/10.1111/j.1365-2990.2007.00907.x.
- Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain. Internet]. 1994 Apr [cited. 2021 Dec];1172:235–243. https://doi.org/10.1093/brain/117.2.235.
- Campese N, Fanciulli A, Stefanova N, et al. Neuropathology of multiple system atrophy: kurt Jellinger`s legacy. J Neural Transm. Internet]. 2021 Oct 1 [cited. 2021 Dec 11];12810:1481–1494. https://doi.org/10.1007/s00702-021-02383-3.
- Peelaerts W, Bousset L, Van Der Perren A, et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. Internet]. 2015 Jun 18 [cited. 2021 Dec 11];5227556:340–344. https://doi.org/10.1038/nature14547.
- Peng C, Gathagan RJ, Lee VMY. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies. Neurobiol Dis. Internet]. 2018 Jan 1 [cited. 2021 Dec 11];109Pt B:209–218. https://doi.org/10.1016/j.nbd.2017.07.018.
- Foguem C, Manckoundia P. Lewy body disease: clinical and pathological “overlap syndrome” between synucleinopathies (parkinson disease) and tauopathies (alzheimer disease). Curr Neurol Neurosci Rep. Internet]. 2018 May 1 [cited. 2021 Dec 11];185: https://doi.org/10.1007/s11910-018-0835-5.
- Savica R, Beach TG, Hentz JG, et al. Lewy body pathology in Alzheimer’s disease: a clinicopathological prospective study. Acta Neurol Scand. Internet]. 2019 Jan 1 [cited. 2021 Dec 11];1391:76–81. https://doi.org/10.1111/ane.13028.
- Buchman AS, Nag S, Leurgans SE, et al. Spinal Lewy body pathology in older adults without an antemortem diagnosis of Parkinson’s disease. Brain Pathol. Internet]. 2018 Jul 1 [cited. 2021 Dec 11];284:560–568. https://doi.org/10.1111/bpa.12560.
- Markesbery WR, Jicha GA, Liu H, et al. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol. Internet]. 2009 Jul [cited. 2021 Dec];687:816–822. https://doi.org/10.1097/NEN.0b013e3181ac10a7.
- Montembeault M, Brambati SM, Lamari F, et al. Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer’s disease cerebrospinal fluid biomarkers. NeuroImage Clin [Internet]. 2018 Jan 1 [cited 2021 Dec 12];20:1018–1025. https://pubmed.ncbi.nlm.nih.gov/30340200/
- Villain N, Dubois B. Alzheimer ’ s disease including focal presentations To cite this version : HAL Id . Seminars in Neurology. 2019;39(2):213–226. hal-02271750 DOI:https://doi.org/10.1055/s-0039-1681041.
- Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the international working group. Lancet Neurol. Internet]. 2021 Jun 1 [cited. 2021 Dec 11];26:484–496. https://doi.org/10.1016/S1474-4422(21)00066-1.
- Robinson JL, Lee EB, Xie SX, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. Internet]. 2018 Jul 1 [cited. 2021 Dec 11];1417:2181–2193. https://doi.org/10.1093/brain/awy146.
- Ossenkoppele R, Lyoo CH, Jester-Broms J, et al. Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological tau in patients with alzheimer disease. JAMA Neurol. Internet]. 2020 May 1 [cited. 2021 Dec 11];775:632–642. https://doi.org/10.1001/jamaneurol.2019.5154.
- Karanth S, Nelson PT, Katsumata Y, et al. Prevalence and clinical phenotype of quadruple misfolded proteins in older adults. JAMA Neurol. Internet]. 2020 Oct 1 [cited. 2021 Dec 11];7710:1299–1307. https://doi.org/10.1001/jamaneurol.2020.1741.
- Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019 Jun 1 [[cited 2021 Dec 11]];142(6):1503–1527. Internet https://pubmed.ncbi.nlm.nih.gov/31039256/
- Di Marco LY, Venneri A, Farkas E, et al. Vascular dysfunction in the pathogenesis of Alzheimer’s disease–A review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis. Internet]. 2015 Feb 28 [cited. 2021 Dec 11];82:593–606. https://doi.org/10.1016/j.nbd.2015.08.014.
- Bennett RE, Robbins AB, Hu M, et al. Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer’s disease. Proc Natl Acad Sci U S A. Internet]. 2018 Feb 6 [cited. 2021 Dec 11];1156:E1289–98. https://doi.org/10.1073/pnas.1710329115.
- Verheijen J, Sleegers K. Understanding Alzheimer disease at the interface between genetics and transcriptomics. Trends Genet. Internet]. 2018 Jun 1 [cited. 2021 Dec 11];346:434–447. https://doi.org/10.1016/j.tig.2018.02.007.
- Naj AC, Schellenberg GD. Genomic variants, genes, and pathways of Alzheimer’s disease: an overview. Am J Med Genet B Neuropsychiatr Genet. Internet]. 2017 Jan 1 [cited. 2021 Dec 11];1741:5–26. https://doi.org/10.1002/ajmg.b.32499.
- Hampel H, Nisticò R, Seyfried NT, et al. Omics sciences for systems biology in Alzheimer’s disease: state-of-the-art of the evidence. Ageing Res Rev. Internet]. 2021 Aug 1 [cited. 2021 Dec 11];69:101346. https://doi.org/10.1016/j.arr.2021.101346.
- Del Prete E, Beatino MF, Campese N, et al. Fluid Candidate biomarkers for alzheimer’s disease: a precision medicine approach. J Pers Med. Internet]. 2020 Nov 1 [cited. 2021 Dec 11];14:1–34. https://doi.org/10.3390/jpm10040221.
- Li JQ, Bi YL, Shen XN, et al. Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders. Transl Neurodegener. Internet]. 2020 Dec 1 [cited. 2021 Dec 11];91: https://doi.org/10.1186/s40035-020-00222-1.
- Wang H, Stewart T, Toledo JB, et al. A longitudinal study of total and phosphorylated α-synuclein with other biomarkers in cerebrospinal fluid of alzheimer’s disease and mild cognitive impairment. J Alzheimers Dis. 2018 [cited 2021 Dec 11];61(4):1541–1553. Internet https://doi.org/10.3233/JAD-171013.
- Majbour NK, Chiasserini D, Vaikath NN, et al. Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease. Sci Rep. Internet]. 2017 Jan 10 [cited. 2021 Dec 11];71: https://doi.org/10.1038/srep40263.
- Lv S, Zhou X, Li Y, et al. The association between plasma α-synuclein (α-syn) protein, urinary alzheimer-associated neuronal thread protein (AD7c-NTP), and apolipoprotein epsilon 4 (ApoE ε4) alleles and cognitive decline in 60 patients with alzheimer’s disease compared with 28 age-matched normal individuals. Med Sci Monit. 2021 [cited 2021 Dec 11];27: Internet https://pubmed.ncbi.nlm.nih.gov/34312362/
- Wang J, Zheng B, Yang S, et al. Differential circulating levels of naturally occurring antibody to α-synuclein in parkinson’s disease dementia, alzheimer’s disease, and vascular dementia. Front Aging Neurosci. Internet]. 2020 Sep 25 [cited. 2021 Dec 11];12: https://doi.org/10.3389/fnagi.2020.571437.
- Simonsen AH, Kuiperij B, El-Agnaf OMA, et al. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomark Med. Internet]. 2016 Jan 1 [cited. 2021 Dec 11];11:19–34. https://doi.org/10.2217/BMM.14.105.
- Shalash A, Salama M, Makar M, et al. Elevated serum α-synuclein autoantibodies in patients with parkinson’s disease relative to alzheimer’s disease and controls. Front Neurol. Internet]. 2017 Dec 22 [cited. 2021 Dec 11];8DEC: https://doi.org/10.3389/fneur.2017.00720.
- Shi M, Tang L, Toledo JB, et al. Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer’s disease. Alzheimers Dement. Internet]. 2018 Aug 1 [cited. 2021 Dec 11];148:1052–1062. https://doi.org/10.1016/j.jalz.2018.02.015.
- García-Ayllón MS, Monge-Argilés JA, Monge-García V, et al. Measurement of CSF α-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer’s disease. J Neurochem. Internet]. 2019 Jul 1 [cited. 2021 Dec 11];152:218–230. https://doi.org/10.1111/jnc.14719.
- Bougea A, Stefanis L, Paraskevas GP, et al. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson’s disease dementia, dementia with Lewy bodies and Alzheimer’s disease. J Neurol. Internet]. 2018 Oct 1 [cited. 2021 Dec 11];26510:2295–2301. https://doi.org/10.1007/s00415-018-8992-7.
- Chiasserini D, Biscetti L, Eusebi P, et al. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia. Alzheimers Res Ther. Internet]. 2017 Jul 28 [cited. 2021 Dec 11];91: https://doi.org/10.1186/s13195-017-0276-4.
- Førland MG, Tysnes OB, Aarsland D, et al. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. Eur J Neurol. Internet]. 2020 Jan 1 [cited. 2021 Dec 11];271:43–50. https://doi.org/10.1111/ene.14032.
- Bousiges O, Philippi N, Lavaux T, et al. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer’s disease and dementia with Lewy bodies from the prodromal stage. Alzheimers Res Ther. Internet]. 2020 Sep 29 [cited. 2021 Dec 11];121: https://doi.org/10.1186/s13195-020-00684-5.
- Graham C, Santiago-Mugica E, Abdel-All Z, et al. Erythrocytes as biomarkers for dementia: analysis of protein content and alpha-synuclein. J Alzheimers Dis. 2019 [cited 2021 Dec 11];71(2):569–580. Internet https://doi.org/10.3233/JAD-190567.
- Hosseini S, Vázquez-Villegas P, Rito-Palomares M, et al. Disadvantages and Modifications of conventional ELISA. SpringerBriefs Appl Sci Technol. Internet]. 2018 [cited. 2022];9789811067655:67–115. DOI: https://doi.org/10.1007/978-981-10-6766-2_5.
- Diaz-Lucena D, Escaramis G, Villar-Piqué A, et al. A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β-amyloid42, total-tau, phospho-tau and α-synuclein in the differential diagnosis of neurodegenerative dementia. J Neurol. Internet]. 2020 Sep 1 [cited. 2021 Dec 11];2679:2567–2581. https://doi.org/10.1007/s00415-020-09870-9.
- Boiten WA, van Steenoven I, Xiao M, et al. Pathologically decreased CSF levels of synaptic marker NPTX2 in DLB are correlated with levels of alpha-synuclein and VGF. Cells. Internet]. 2020 Jan 1 [cited. 2021 Dec 11];11:1–13. https://doi.org/10.3390/cells10010038.
- DuPont NC, Wang K, Wadhwa PD, et al. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol. Internet]. 2005 Aug [cited. 2022 Apr];662:175–191. https://doi.org/10.1016/j.jri.2005.03.005.
- Youssef P, Kim W S, Halliday G M, Lewis S JG and Dzamko N. Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson’s Disease Patients. JPD, 11(4), 1761–1772. https://doi.org/10.3233/JPD-212694
- Nash Y, Schmukler E, Trudler D, et al. DJ-1 deficiency impairs autophagy and reduces alpha-synuclein phagocytosis by microglia. J Neurochem. Internet]. 2017 Dec 1 [cited. 2021 Dec 11];1435:584–594. https://doi.org/10.1111/jnc.14222.
- Laske C, Fallgatter AJ, Stransky E, et al. Decreased α-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer’s disease patients and control subjects. Dement Geriatr Cogn Disord. Internet]. 2011 Aug [cited. 2021 Dec];316:413–416. https://doi.org/10.1159/000329763.
- Barrie ES, Lee SH, Frater JT, et al. Alpha-synuclein mRNA isoform formation and translation affected by polymorphism in the human SNCA 3ʹUTR. Mol Genet Genomic Med. Internet]. 2018 Jul 1 [cited. 2021 Dec 11];64:565–574. https://doi.org/10.1002/mgg3.407.
- Scheckel C, Aguzzi A. Prions, prionoids and protein misfolding disorders. Nat Rev Genet. Internet]. 2018 Jul 1 [cited. 2021 Dec 11];197:405–418. https://doi.org/10.1038/s41576-018-0011-4.
- Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. Internet]. 2010 Jul [cited. 2021 Dec];337:317–325. https://doi.org/10.1016/j.tins.2010.04.003.
- Aguzzi A. Cell biology: beyond the prion principle. Nature. Internet]. 2009 Jun 18 [cited. 2021 Dec 11];4597249:924–925. https://doi.org/10.1038/459924a.
- Alper T, Haig DA, Clarke MC. The scrapie agent: evidence against its dependence for replication on intrinsic nucleic acid. J Gen Virol. 1978;41(3):503–516.
- Alper T, Cramp WA, Haig DA, et al. Does the agent of scrapie replicate without nucleic acid? Nature. Internet]. 1967 [cited. 2021];2145090:764–766. DOI: https://doi.org/10.1038/214764a0.
- Griffith JS. Self-replication and scrapie. Nature. Internet]. 1967 [cited. 2021];2155105:1043–1044. DOI: https://doi.org/10.1038/2151043a0.
- Đồng T, Satoh K The latest research on rt-quic assays-a literature review. Pathog (Basel Switzerland) [Internet]. 2021 Mar 1 [cited 2021 Dec 11];10( 3):1–11. https://pubmed.ncbi.nlm.nih.gov/33807776/
- Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature. Internet]. 2001 Jun 14 [cited. 2021 Dec 11];4116839:810–813. https://doi.org/10.1038/35081095.
- Rubenstein R, Chang B. Re-assessment of PrP(Sc) distribution in sporadic and variant CJD. PLoS One. Internet]. 2013 Jul 3 [cited. 2021 Dec 11];87:e66352. https://doi.org/10.1371/journal.pone.0066352.
- Bougard D, Brandel JP, Bélondrade M, et al. Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci Transl Med. Internet]. 2016 Dec 21 [cited. 2021 Dec 11];8370: https://doi.org/10.1126/scitranslmed.aag1257.
- Moda F, Gambetti P, Notari S, et al. Prions in the urine of patients with variant Creutzfeldt-Jakob disease. N Engl J Med. Internet]. 2014 Aug 7 [cited. 2021 Dec 11];3716:530–539. https://doi.org/10.1056/NEJMoa1404401.
- Campese N, Beatino MF, Del Gamba C, et al. Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer’s and other neurodegenerative diseases. Expert Rev Neurother. 2021 [cited 2021 Dec 11];21(9):949–967. Internet https://doi.org/10.1080/14737175.2021.1965879.
- Atarashi R, Satoh K, Sano K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med. Internet]. 2011 Feb [cited. 2021 Dec];172:175–178. https://doi.org/10.1038/nm.2294.
- Bongianni M, Ladogana A, Capaldi S, et al. α-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Ann Clin Transl Neurol. Internet]. 2019 Oct 1 [cited. 2021 Dec 12];610:2120–2126. https://doi.org/10.1002/acn3.50897.
- Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. Internet]. 2016 Oct 1 [cited. 2021 Dec 11];310:812–818. https://doi.org/10.1002/acn3.338.
- Manne S, Kondru N, Hepker M, et al. Ultrasensitive detection of aggregated α-synuclein in glial cells, human cerebrospinal fluid, and brain tissue using the RT-quic assay: new high-throughput neuroimmune biomarker assay for parkinsonian disorders. J Neuroimmune Pharmacol. Internet]. 2019 Sep 15 [cited. 2021 Dec 11];143:423–435. https://doi.org/10.1007/s11481-019-09835-4.
- Shahnawaz M, Tokuda T, Waraga M, et al. Development of a biochemical diagnosis of parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. Internet]. 2017 Feb 1 [cited. 2021 Dec 11];742:163–172. https://doi.org/10.1001/jamaneurol.2016.4547.
- Ning H, Wu Q, Han D, et al. Baseline concentration of misfolded α-synuclein aggregates in cerebrospinal fluid predicts risk of cognitive decline in Parkinson’s disease. Neuropathol Appl Neurobiol. Internet]. 2019 Jun 1 [cited. 2021 Dec 11];454:398–409. https://doi.org/10.1111/nan.12524.
- Garrido A, Fairfoul G, Tolosa ES, et al. α-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson’s disease. Ann Clin Transl Neurol. 2019 Jun 1;6(6):1024–1032.
- Brockmann K, Quadalti C, Lerche S, et al. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun. Internet]. 2021 Dec 1 [cited. 2022 Apr 3];91: https://doi.org/10.1186/s40478-021-01276-6.
- Orrù CD, Ma TC, Hughson AG, et al. A rapid α-synuclein seed assay of Parkinson’s disease CSF panel shows high diagnostic accuracy. Ann Clin Transl Neurol. Internet]. 2021 Feb 1 [cited. 2021 Dec 11];82:374–384. https://doi.org/10.1002/acn3.51280.
- Shahnawaz M, Mukherjee A, Pritzkow S, et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature. Internet]. 2020 Feb 13 [cited. 2021 Dec 11];5787794:273–277. https://doi.org/10.1038/s41586-020-1984-7.
- Singer W, Schmeichel AM, Shahnawaz M, et al. Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from lewy body synucleinopathies. Ann Neurol. Internet]. 2020 Sep 1 [cited. 2021 Dec 11];883:503–512. https://doi.org/10.1002/ana.25824.
- Kang UJ, Boehme AK, Fairfoul G, et al. Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson’s disease. Mov Disord. Internet]. 2019 Apr 1 [cited. 2021 Dec 11];344:536–544. https://doi.org/10.1002/mds.27646.
- Iranzo A, Fairfoul G, Ayudhaya ACN, et al. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. Internet]. 2021 Mar 1 [cited. 2021 Dec 11];23:203–212. https://doi.org/10.1016/S1474-4422(20)30449-X.
- Singer W, Schmeichel AM, Shahnawaz M, et al. Alpha-synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Ann Neurol. Internet]. 2021 Jun 1 [cited. 2021 Dec 11];896:1212–1220. https://doi.org/10.1002/ana.26089.
- Quadalti C, Calandra-Buonaura G, Baiardi S, et al. Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. NPJ Park Dis. Internet]. 2021 Dec 1 [cited. 2021 Dec 11];71: https://pubmed.ncbi.nlm.nih.gov/34635674/
- Donadio V, Wang Z, Incensi A, et al. In vivo diagnosis of synucleinopathies: a comparative study of skin biopsy and RT-QuIC. Neurology. Internet]. 2021 May 18 [cited. 2021 Dec 11];9620:e2513–24. https://doi.org/10.1212/WNL.0000000000011935.
- Mammana A, Baiardi S, Quadalti C, et al. RT-QuIC detection of pathological α-synuclein in skin punches of patients with lewy body disease. Mov Disord. Internet]. 2021 Sep 1 [cited. 2021 Dec 11];369:2173–2177. https://doi.org/10.1002/mds.28651.
- Wang Z, Becker K, Donadio V, et al. Skin α-synuclein aggregation seeding activity as a novel biomarker for parkinson disease. JAMA Neurol. Internet]. 2020 Jan 1 [cited. 2021 Dec 12];781:30–40. https://doi.org/10.1001/jamaneurol.2020.3311.
- Perra D, Bongianni M, Novi G, et al. Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies. Brain Commun. Internet]. 2021 Apr 5 [cited. 2021 Dec 11];32: https://doi.org/10.1093/braincomms/fcab045.
- Stefani A, Iranzo A, Holzknecht E, et al. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain. Internet]. 2021 Apr 1 [cited. 2021 Dec 11];1444:1118–1126. https://doi.org/10.1093/brain/awab005.
- Oppedal K, Borda MG, Ferreira D, et al. European DLB consortium: diagnostic and prognostic biomarkers in dementia with Lewy bodies, a multicenter international initiative. Neurodegener Dis Manag. Internet]. 2019 Oct [cited. 2021 Dec];95:247–250. https://doi.org/10.2217/nmt-2019-0016.
- Wang ZY, Han ZM, Liu QF, et al. Use of CSF α-synuclein in the differential diagnosis between Alzheimer’s disease and other neurodegenerative disorders. Int Psychogeriatrics. Internet]. 2015 Jan 9 [cited. 2021 Dec 11];279:1429–1438. https://doi.org/10.1017/S1041610215000447.
- Giampietri L, Belli E, Beatino MF, et al. Fluid biomarkers in Alzheimer’s disease and other neurodegenerative disorders: toward integrative diagnostic frameworks and tailored treatments. Diagnostics. Internet]. 2022 Mar 24 [cited. 2022 Apr 12];124:796. https://doi.org/10.3390/diagnostics12040796.
- Abdelhak A, Foschi M, Abu-Rumeileh S, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. Internet]. 2022 Mar 1 [cited. 2022 Apr 12];183:158–172. https://doi.org/10.1038/s41582-021-00616-3.
- Hansson O, Rutz S, Zetterberg H, et al. Pre-analytical protocol for measuring Alzheimer’s disease biomarkers in fresh CSF. Alzheimer’s Dement (Amsterdam Netherlands) [Internet]. 2020 [cited 2021 Dec 11];12( 1). Available from: https://pubmed.ncbi.nlm.nih.gov/33354617/
- Sabbagh MN, Boada M, Borson S, et al. Early Detection of Mild Cognitive Impairment (MCI) in Primary Care. J Prev Alzheimer’s Dis. 2020 Mar 1;7(3):165–170.
- Barbour R, Kling K, Anderson JP, et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis. Internet]. 2008 Jan [cited. 2022 Apr];52:55–59. https://doi.org/10.1159/000112832.
- Toschi N, Lista S, Baldacci F, et al. Biomarker-guided clustering of Alzheimer’s disease clinical syndromes. Neurobiol Aging. Internet]. 2019 Nov 1 [cited. 2021 Dec 11];83:42–53. https://doi.org/10.1016/j.neurobiolaging.2019.08.032.
- Hampel H, Lista S, Neri C, et al. Time for the systems-level integration of aging: resilience enhancing strategies to prevent Alzheimer’s disease. Prog Neurobiol. Internet]. 2019 Oct 1 [cited. 2021 Dec 11];181:101662. https://doi.org/10.1016/j.pneurobio.2019.101662.
- Hampel H, Goetzl EJ, Kapogiannis D, et al. Biomarker-drug and liquid biopsy Co-development for disease staging and targeted therapy: cornerstones for Alzheimer’s precision medicine and pharmacology. Front Pharmacol. 2019 [Internet]. [ [Internet]];10(MAR): https://doi.org/10.3389/fphar.2019.00310.
- CADRO: Common Alzheimer’s Disease Research Ontology | National Institute on Aging [Internet]. [cited 2021 Dec 12]. Available from: https://www.nia.nih.gov/news/cadro-common-alzheimers-disease-research-ontology
- My WordPress – just another WordPress site [Internet]. [cited 2021 Dec 12]. Available from: https://npmiweb.net/
- ENIGMA [Internet]. [cited 2021 Dec 12]. Available from: http://enigma.ini.usc.edu/